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A B S T R A C T
The mainstay of treatment for unresectable hepatocellular carcinoma is locoregional therapy
including percutaneous ablation and transarterial chemo- and radioembolization.While moni-
toring for tumor response after transarterial chemoembolization is crucial, current imaging
strategies are suboptimal. The standard of care is contrast-enhanced magnetic resonance
imaging or computed tomography imaging performed at least 4 to 6 weeks after therapy.
We present a case in which contrast-enhanced ultrasound identified a specific extra-
hepatic collateral from the gastroduodenal artery supplying residual viable tumor and assisting
with directed transarterial management.
© 2018 the Authors. Published by Elsevier Inc. under copyright license from the University
ofWashington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Initially reported in 1968, microbubble and ultrasound
contrast research gained considerable momentum in the
late 20th and early 21st century [1]. By 2000, clinical guide-
lines on the use of contrast-enhanced ultrasound (CEUS)
had been established in echocardiography. In 2004, the
European Federation of Societies for Ultrasound in Medicine
and Biology established similar guidelines for CEUS in
hepatology [2]. More recently, CEUS has been applied to
pancreatic pathology, alimentary disease, and even extravas-
cular (urinary, lymphatic, biliary, and subcutaneous)
examinations [3].
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In patients with hepatocellular carcinoma, locoregional
therapy can be offered for whom surgical resection is not an
immediate option [4]. Therapies include percutaneous abla-
tion (chemical or thermal) and transarterial embolization (bland,
radiomicrospheres, or chemotherapy) [4].These therapies may
serve as a bridge to transplant [4]. However, assessing treatment
effect after locoregional therapy is essential to determining the
success of downstaging or need for retreatment. The modi-
fied Response Evaluation Criteria in Solid Tumors (mRECIST)
guidelines adapted from theAmericanAssociation for the Study
of Liver Diseases provide a standardized language to assess
tumor response to locoregional therapy on imaging [5].
CEUS is increasingly being studied as a useful and early
adjunct to cross-sectional imaging (computed tomography [CT]
or magnetic resonance imaging [MRI]) for monitoring treat-
ment effect [2,3]. Current literature concedes that cross-
sectional imaging to evaluate response should be performed
at least 4 to 6 weeks after treatment to distinguish viable tumor
from postembolization inflammation [6–8]. In addition, the iden-
tification and management of residual disease requires an
accurate characterization of the tumor vascular pedicle and
a failure to appreciate parallel visceral or systemic vascula-
ture can lead to treatment failure and organ damage from
nontargeted delivery of embolization agents [9]. However, extra-
anatomic (extrahepatic) collateralization to the hepatocellular
tumor bed is not uncommon [9].We report a case in which CEUS
characterized a specific extrahepatic collateral to a hepatocel-
lular carcinoma recurrence just 2 weeks after transarterial
chemoembolization (TACE)—allowing for targetedmanagement.
Case report
A 68-year-old male with a known history of hepatitis C related
cirrhosis, was diagnosed by CT abdomen with a 5.5 cm segment
3/4b hepatocellular carcinoma. The patient underwent a
transjugular liver biopsy that confirmed cirrhosis. A hepatic
venous pressure gradient of 13 mm Hg was reported. The pa-
tient’s Model for End-Stage Liver Disease score was 9 (Child
Pugh A).
The patient was referred to interventional radiology for
evaluation for locoregional therapy. A preprocedural MRI
was performed (Fig. 1a). The patient was prepared for TACE
(ultimately TACE treatment #1). The patient underwent digital
subtraction angiography (DSA) followed by conventional
chemoembolization using a doxorubicin and mitomycin
lipiodol suspension via the hepatic arterial segment 3 branch
(Fig. 1b). Completion DSA showed sluggish to cessation of
flow through the target artery. The patient then underwent
an interval liver protocol MRI 5 weeks after TACE (treatment
#1) to monitor for treatment effect with initial interpretation
felt to be at least partial response by mRECIST criteria (Fig. 1c).
Two smaller mildly enhancing lesions (1.6 cm and 1.1 cm)
within the treated lesion both persisted on delayed phase
(Fig. 1d) and were favored to reflect post-treatment granula-
tion tissue rather than residual tumor disease. A follow-up
MRI was recommended.
Follow-up MRI 12 weeks after this last MRI (and a total of
17 weeks after TACE treatment #1) revealed that both lesions
now showed unambiguous evidence of arterial enhancement
with washout (Figs. 2a and 2b) consistent with viable tumor.
No extrahepatic arterial supply was appreciated on MRI. The
patient underwent repeat arteriography that demonstrated a
supply to the tumor from the segment 4 hepatic artery branch
(Fig. 2c). Conventional chemoembolization was performed from
this vessel (TACE treatment #2). Completion DSA showed slug-
gish to cessation of flow through the target artery.
To monitor treatment effect as part of a multicenter clin-
ical trial (NCT02764801) with Institutional Review Board
approval, CEUS was performed 2 weeks after this secondTACE
treatment (Figs. 3a and 3b). CEUS showed tumor viability and
Fig. 1 – (a) Fat saturated T2 post-contrast sequence magnetic resonance imaging (MRI) depicts a 5.5 cm segment 3/4b
hepatocellular carcinoma (arrow). Transarterial chemoembolization of the lesion was subsequently performed (treatment
#1). (b) Digital subtraction angiography via the distal left hepatic artery shows an avidly enhancing mass arising from
segment 3/4b (arrow). To monitor treatment effect, (c) T1-weighted post-contrast sequence MRI was performed 5 weeks
after transarterial chemoembolization and shows a 1.6 cm (arrow) and 1.1 cm (arrowhead) mildly enhancing nodular lesion
with (d) persistent enhancement on delayed phase fat saturated T1 sequence. This was initially believed to reflect post-
treatment inflammation and the patient was referred for interval MRI.
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perfusion via an extrahepatic collateral that was traced to the
gastroduodenal artery (Fig. 3b). An MRI was performed 2 weeks
after CEUS (a total of 4 weeks from the second TACE treat-
ment) confirming arterial enhancement with continued
washout of both lesions (Figs. 4a and 4b) consistent with stable
disease by mRECIST criteria. Consequently, the patient was
brought back for repeat treatment angiography and under-
went coil embolization of the gastroduodenal artery (Figs. 4c
and 4d) along with percutaneous ethanol injection of the tumor
bed. Subsequent MRI (Figs. 5a and 5b) 1 week postcoil embo-
lization showed complete regression of the larger lesion (partial
response by mRECIST criteria owing to persistence of the
smaller nodule). The tumor was successfully down-staged in
preparation for potential liver transplantation.
Discussion
In this patient, CEUS provided key information regarding both
residual tumor viability and a specific collateral that was main-
taining tumor perfusion.As noted, parasitized collateral arterial
supplies can be a source failure of locoregional control [10]. Risk
factors for the development of extrahepatic collateralization
Fig. 2 – Interval magnetic resonance imaging (MRI) was performed of the lesion 12 weeks after the last MRI (a total of 17
weeks after transarterial chemoembolization treatment #1) to monitor for residual tumor viability. (a) Fat saturated T1
post-contrast sequence MRI shows 2.3 cm (arrow) and 1.1 cm (arrowhead) arterially enhancing lesions (previously 1.6 cm
and 1.1 cm) with unambiguous evidence of washout on (b) delayed phase fat saturated T1 sequence. Highly suggestive of
residual tumor viability, the patient was taken back for transarterial chemoembolization (treatment #2). (c) Digital
subtraction angiography depicts the left hepatic artery and selection of the medial segment (arrow) for intra-arterial
treatment.
Fig. 3 – Two weeks after transarterial chemoembolization treatment #2, contrast-enhanced ultrasound was performed to
monitor for residual tumor viability as part of an experimental protocol. (a) Grayscale hepatic ultrasound demonstrates a
heterogeneous hypoechoic tumor (arrow). (b) Contrast-enhanced hepatic ultrasound demonstrates post-treatment cavity
(arrow) and presence of vascular residual tumor (star). Traceable extrahepatic collateral is identified (arrowhead). This was
traced back to the gastroduodenal artery.
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include tumor size (greater than 5 cm), tumor location (pe-
ripheral or nonperitonealized or exophytic extension), and
hepatic artery attenuation (from intervention or tumor biology)
[10,11]. Other commonly identified sources of aberrant hepatic
tumor vascularization include the right inferior phrenic, omental
branches, right internal mammary, right intercostal arteries,
right renal or adrenal arteries, and the superior mesenteric
artery [11]. In fact, the most commonly identified extrahe-
patic feeding vessels identified are the inferior phrenic artery
(owing to the bare area of the liver) and omental branches (for
exophytic masses) [11].
Post-treatment surveillance by MRI or CT is frequently
delayed by at least 4-6 weeks after each treatment cycle to allow
for maturation of granulation tissue, limit lipiodol-associated
artifacts, and help separate viable tumor from postembolization
inflammation [6,12]. In fact, treatment artifact may last for as
long as 3 months [6,12]. Utilizing CEUS, tumor viability via a
specific extrahepatic collateralization was appreciated in this
patient within just 2 weeks after treatment, confirming the need
for retreatment and assisting with planning.
CEUS is particularly suited for the vascular assessment
of the viability of lesions. Contrast agents used in CEUS are
Fig. 4 – Four weeks after transarterial chemoembolization treatment #2, magnetic resonance imaging was performed as
part of our institutional standard-of-care to monitor for residual tumor viability. (a) Fat saturated T1 post-contrast sequence
magnetic resonance imaging shows continued evidence of 2.2 cm (arrow) and 1.0 cm (arrowhead) arterially enhancing
lesions (previously 2.3 cm and 1.1 cm) with washout on (b) delayed phase fat saturated T1 sequence. The patient was
brought back to the interventional suite for additional treatment. (c) Digital subtraction angiography via the gastroduodenal
artery demonstrates collateralization from the gastroduodenal artery (arrow) to the inferomedial portion of the tumor bed
(arrowhead). (d) Angiography via the common hepatic artery shows successful coil embolization of the gastroduodenal
artery (arrow) and no tumor enhancement.
Fig. 5 – One week after bland coil embolization of the gastroduodenal artery and ethanol ablation of the tumor, magnetic
resonance imaging was again performed to monitor for residual tumor viability. (a) Fat saturated T1-weighted post-contrast
sequence magnetic resonance imaging shows regression of the larger nodular lesion within the inferomedial treatment
cavity (arrow) with persistence of the smaller 1.1 cm lesion (arrowhead) with washout (of the smaller lesion) on (b) delayed
fat saturated T1 sequence.
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microbubbles of gas stabilized by a protein, lipid or phospho-
lipid shell and approximate the size of circulating red blood
cells [13,14].They remain in the intravascular space until cleared
by the lungs via exhalation—unlike CT and MRI contrast agents
which can distribute into the interstitial space [15]. Further-
more, by establishing a difference in acoustic impedance
between the surrounding tissues, ultrasound contrast agents
improve signal enhancement within active vessels by up to
25 dB [14].
Additionally, CEUS has several advantages over cross-
sectional imaging. Ultrasound contrast agents are not
hepatotoxic or nephrotoxic [2]. There is no ionizing radiation
exposure. There is no contraindication to imaging in patients
with metallic implants. Compared with MRI, imaging is much
more rapid and less anxiety-provoking to the patient. Finally,
hepatic evaluation via CEUS may have a lower cost than MRI
and CT [16].
However, notable limitations exist with CEUS examina-
tion. Ultrasound is operator-dependent with noted inter- and
intrareader variability [12]. This may be emphasized in cases
of limited examination (such as with obese body habitus) or
multiple nontarget tumors [17]. New lesions may be missed
[17]. It is not yet easily feasible to interrogate the entire liver
(instead only known areas of interest) through all vascular
phases with CEUS, unlike cross-sectional imaging [2]. Lesions
that are exceedingly deep, anatomically obscured by the dia-
phragm or lung, or hypovascular may also be challenging to
characterize by CEUS [2,18]. Additionally, interpretation of
hepatic CEUS can be complicated in patients with cirrhosis
because of heterogeneous parenchymal enhancement [2,17].
In this clinical case, CEUS not only showed early evidence
of residual disease after TACE but also identified a specific col-
lateral of concern. While certainly creating a comprehensive
vascular roadmap with CEUS in the absence of cross-sectional
imaging would be inordinately challenging, the benign safety
profile of ultrasound contrast agents in combination with the
potential for real-time imaging with sonography has spurred
significant research interest [17,19–21]. Increasingly powered
prospective randomized controlled trials are currently being
performed and will add value to the limited body of litera-
ture on the role of CEUS in TACE treatment monitoring in
hepatocellular carcinoma.
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